Article

Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cells

2020-05-08

Abstract excerpt

<h4>Background</h4> CDK4/6 inhibitors such as ribociclib are becoming widely used targeted therapies in hormone-receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) breast cancer. However, cancers can advance due to drug resistance, a problem in which tumor heterogeneity and evolution are key features. <h4>Methods</h4> Ribociclib-resistant HR+/HER2-CAMA-1 breast cancer cells were gen...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: edbb5ff3-b768-5050-a00f-9ebf5cc2898d
DOI: 10.1101/2020.05.07.082073

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cellsDOI 10.1101/2020.05.07.082073Read

Heterogeneous therapy-resistant cancer cells have distinct and exploitable drug sensitivity profilesSemantic proximity Read

Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell linesSemantic proximity Read

Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunitiesSemantic proximity Read

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancerSemantic proximity Read

Sensitization of resistant cells with a BET bromodomain inhibitor in a cell culture model of deep intrinsic resistance in breast cancerSemantic proximity Read

A ‘one-two punch’ therapy strategy to target chemoresistance in estrogen receptor positive breast cancerSemantic proximity Read

Chemotherapy reshapes cellular clonal landscape via persister programs in breast cancer xenograftsSemantic proximity Read

The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast CancerSemantic proximity Read

The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assaysSemantic proximity Read

Detecting radio- and chemoresistant cells in 3D cancer co-cultures using chromatin biomarkersSemantic proximity Read

Combating subclonal evolution of resistant cancer phenotypes.Semantic proximity Read

Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine inhibitorsSemantic proximity Read